Latent expression of the Epstein-Barr virus (EBV)-encoded major histocompatibility complex class I TAP inhibitor, BNLF2a, in EBV-positive gastric carcinomas

Journal of Virology

Volumn 89, Issue 19, 2015, Pages 10110-10114

  Strong, Michael J ^a,b   Laskow, Thomas ^a,b   Nakhoul, Hani ^a,b   Blanchard, Eugene ^c   Liu, Yaozhong ^a   Wang, Xia ^a   Baddoo, Melody ^a,b   Lin, Zhen ^a,b   Yin, Qinyan ^a,b   Flemington, Erik K ^a,b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; ABC TRANSPORTER; BNLF21 PROTEIN, HUMAN HERPESVIRUS 4; HLA ANTIGEN CLASS 1; MATRIX PROTEIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING (TAP);

ARTICLE; BNLF2A GENE; DISEASE ACTIVITY; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENOME ANALYSIS; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; STOMACH CARCINOGENESIS; STOMACH CARCINOMA; VIRUS GENE; VIRUS GENOME; VIRUS IDENTIFICATION; VIRUS LATENCY; ANTAGONISTS AND INHIBITORS; EPSTEIN BARR VIRUS INFECTION; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; METABOLISM; STOMACH TUMOR; TUMOR ESCAPE; VIROLOGY;

ATP-BINDING CASSETTE TRANSPORTERS; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION; GENES, VIRAL; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOST-PATHOGEN INTERACTIONS; HUMANS; STOMACH NEOPLASMS; TUMOR ESCAPE; VIRAL MATRIX PROTEINS;

EID: 84940987152     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01110-15     Document Type: Article

References (17)

1. Strong MJ, Xu G, Coco J, Baribault C, Vinay DS, Lacey MR, Strong AL, Lehman TA, Seddon MB, Lin Z, Concha M, Baddoo M, Ferris M, Swan KF, Sullivan DE, Burow ME, Taylor CM, Flemington EK. 2013. Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. PLoS Pathog 9:e1003341. http://dx.doi.org/10.1371/journal.ppat.1003341.
2. Bell MJ, Abbott RJ, Croft NP, Hislop AD, Burrows SR. 2009. An HLA-A2-restricted T-cell epitope mapped to the BNLF2a immune evasion protein of Epstein-Barr virus that inhibits TAP. J Virol 83:2783-2788. http://dx.doi.org/10.1128/JVI.01724-08.
3. Horst D, van Leeuwen D, Croft NP, Garstka MA, Hislop AD, Kremmer E, Rickinson AB, Wiertz EJ, Ressing ME. 2009. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. J Immunol 182:2313-2324. http://dx.doi.org/10.4049/jimmunol.0803218.
4. Croft NP, Shannon-Lowe C, Bell AI, Horst D, Kremmer E, Ressing ME, Wiertz EJ, Middeldorp JM, Rowe M, Rickinson AB, Hislop AD. 2009. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog 5:e1000490. http://dx.doi.org/10.1371/journal.ppat.1000490.
5. Horst D, Favaloro V, Vilardi F, van Leeuwen HC, Garstka MA, Hislop AD, Rabu C, Kremmer E, Rickinson AB, High S, Dobberstein B, Ressing ME, Wiertz EJ. 2011. EBV protein BNLF2a exploits host tailanchored protein integration machinery to inhibit TAP. J Immunol 186: 3594-3605. http://dx.doi.org/10.4049/jimmunol.1002656.
6. Wycisk AI, Lin J, Loch S, Hobohm K, Funke J, Wieneke R, Koch J, Skach WR, Mayerhofer PU, Tampe R. 2011. Epstein-Barr viral BNLF2a protein hijacks the tail-anchored protein insertion machinery to block antigen processing by the transport complex TAP. J Biol Chem 286: 41402-41412. http://dx.doi.org/10.1074/jbc. M111.237784.
7. Hislop AD, Ressing ME, van Leeuwen D, Pudney VA, Horst D, Koppers-Lalic D, Croft NP, Neefjes JJ, Rickinson AB, Wiertz EJ. 2007. A CD8+T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 204:1863-1873. http://dx.doi.org/10.1084/jem.20070256.
8. The Cancer Genome Atlas Research Network. 2014. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202-209. http://dx.doi.org/10.1038/nature13480.
9. Cao S, Strong MJ, Wang X, Moss WN, Concha M, Lin Z, O'Grady T, Baddoo M, Fewell C, Renne R, Flemington EK. 2015. High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project. J Virol 89:713-729. http://dx.doi.org/10.1128/JVI.02570-14.
10. Strong MJ, Baddoo M, Nanbo A, Xu M, Puetter A, Lin Z. 2014. Comprehensive high-throughput RNA sequencing analysis reveals contamination of multiple nasopharyngeal carcinoma cell lines with HeLa cell genomes. J Virol 88:10696-10704. http://dx.doi.org/10.1128/JVI.01457-14.
11. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. 2013. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29:15-21. http://dx.doi.org/10.1093/bioinformatics/bts635.
12. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jane-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA. 2012. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607. http://dx.doi.org/10.1038/nature11003.
13. Lin Z, Puetter A, Coco J, Xu G, Strong MJ, Wang X, Fewell C, Baddoo M, Taylor C, Flemington EK. 2012. Detection of murine leukemia virus in the Epstein-Barr virus-positive human B-cell line JY, using a computational RNA-seq-based exogenous agent detection pipeline, PARSES. J Virol 86:2970-2977. http://dx.doi.org/10.1128/JVI.06717-11.
14. Lin Z, Wang X, Strong MJ, Concha M, Baddoo M, Xu G, Baribault C, Fewell C, Hulme W, Hedges D, Taylor CM, Flemington EK. 2013. Whole-genome sequencing of the Akata and Mutu Epstein-Barr virus strains. J Virol 87:1172-1182. http://dx.doi.org/10.1128/JVI.02517-12.
15. Kim DN, Seo MK, Choi H, Kim SY, Shin HJ, Yoon AR, Tao Q, Rha SY, Lee SK. 2013. Characterization of naturally Epstein-Barr virus-infected gastric carcinoma cell line YCCEL1. J Gen Virol 94:497-506. http://dx.doi.org/10.1099/vir.0.045237-0.
16. Ku JL, Kim KH, Choi JS, Kim SH, Shin YK, Chang HJ, Bae JM, Kim YW, Lee JH, Yang HK, Kim WH, Jeong SY, Park JG. 2012. Establishment and characterization of six human gastric carcinoma cell lines, including one naturally infected with Epstein-Barr virus. Cell Oncol 35:127-136. http://dx.doi.org/10.1007/s13402-012-0073-9.
17. Oh ST, Cha JH, Shin DJ, Yoon SK, Lee SK. 2007. Establishment and characterization of an in vivo model for Epstein-Barr virus positive gastric carcinoma. J Med Virol 79:1343-1348. http://dx.doi.org/10.1002/jmv.20876.